SpyBiotech

SpyBiotech is a clinical-stage biotechnology company developing vaccines using its proprietary protein superglue technology, which enables efficient and stable attachment of antigens to virus-like particle and viral vector delivery platforms.

The approach improves immunogenicity and reduces manufacturing complexity relative to conventional conjugation methods.

Its lead programme targets human cytomegalovirus, with additional candidates in development for Epstein-Barr virus, malaria, and cancer.